On March 8, 2022 Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, reported the acceptance of an abstract for presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in New Orleans to be held April 8–13, 2022 (Press release, Alpine Immune Sciences, MAR 8, 2022, View Source [SID1234609639]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Results from the dose escalation portion of NEON-1, a Phase 1 clinical trial of davoceticept (ALPN-202) as monotherapy will be presented in a Minisymposium as follows:
Presentation Title: Monotherapy dose escalation of davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1)
Session Title: Immunotherapy Combination Strategies in Clinical Trials
Session Date, Time: Tuesday, April 12, 2:30pm–4:30pm CDT
Presentation Number: CT041
The abstract for the oral presentation will be live on the AACR (Free AACR Whitepaper) website on April 8. A copy of the oral presentation slides will be available on the Scientific Publications page of Alpine’s website on April 12 following the presentation.
About Davoceticept (ALPN-202)
Davoceticept (ALPN-202) is a first-in-class, conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer. Preclinical studies of davoceticept have successfully demonstrated superior efficacy in tumor models compared to checkpoint inhibition alone. Completion of dose escalation and initiation of expansion cohorts of NEON-1 (NCT04186637), a Phase 1 monotherapy dose escalation and expansion trial in patients with advanced malignancies, is anticipated in the first half of 2022. NEON-2 (NCT04920383), a combination trial of davoceticept (ALPN-202) and pembrolizumab was initiated in June 2021 and is currently on partial clinical hold.